Advanced Proteome Therapeutics Stock Performance
| APTCF Stock | USD 0.0002 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Advanced Proteome are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Advanced Proteome Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable fundamental indicators, Advanced Proteome is not utilizing all of its potentials. The recent stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 822.4 K | |
| Total Cashflows From Investing Activities | -13.8 K |
Advanced |
Advanced Proteome Relative Risk vs. Return Landscape
If you would invest 0.02 in Advanced Proteome Therapeutics on September 2, 2024 and sell it today you would earn a total of 0.00 from holding Advanced Proteome Therapeutics or generate 0.0% return on investment over 90 days. Advanced Proteome Therapeutics is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Advanced, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Advanced Proteome Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Advanced Proteome's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Advanced Proteome Therapeutics, and traders can use it to determine the average amount a Advanced Proteome's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| APTCF |
Based on monthly moving average Advanced Proteome is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Advanced Proteome by adding Advanced Proteome to a well-diversified portfolio.
Advanced Proteome Fundamentals Growth
Advanced Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Advanced Proteome, and Advanced Proteome fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Advanced Pink Sheet performance.
| Return On Asset | -1.07 | |||
| Current Valuation | 660.53 K | |||
| Shares Outstanding | 41.13 M | |||
| Price To Earning | 2.98 X | |||
| Price To Book | 4.92 X | |||
| EBITDA | 631.22 K | |||
| Cash And Equivalents | 761.6 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 227.41 K | |||
| Debt To Equity | 4.65 % | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (693.58 K) | |||
| Earnings Per Share | 0.02 X | |||
| Total Asset | 636.41 K | |||
About Advanced Proteome Performance
By analyzing Advanced Proteome's fundamental ratios, stakeholders can gain valuable insights into Advanced Proteome's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Advanced Proteome has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Advanced Proteome has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States. Its platform is dedicated to applications in the field of antibody drug conjugates, as well as focused on protein conjugates and immunomodulation. Advanced Proteome operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Advanced Proteome performance evaluation
Checking the ongoing alerts about Advanced Proteome for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Advanced Proteome help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Advanced Proteome generated a negative expected return over the last 90 days | |
| Advanced Proteome has some characteristics of a very speculative penny stock | |
| Advanced Proteome Therapeutics has accumulated 227.41 K in total debt with debt to equity ratio (D/E) of 4.65, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Advanced Proteome has a current ratio of 0.54, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Advanced Proteome until it has trouble settling it off, either with new capital or with free cash flow. So, Advanced Proteome's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Advanced Proteome sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Advanced to invest in growth at high rates of return. When we think about Advanced Proteome's use of debt, we should always consider it together with cash and equity. | |
| Advanced Proteome Therapeutics has accumulated about 761.6 K in cash with (693.58 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Advanced Proteome's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Advanced Proteome's stock is overvalued or undervalued compared to its peers.
- Examining Advanced Proteome's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Advanced Proteome's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Advanced Proteome's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Advanced Proteome's pink sheet. These opinions can provide insight into Advanced Proteome's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Advanced Pink Sheet analysis
When running Advanced Proteome's price analysis, check to measure Advanced Proteome's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Advanced Proteome is operating at the current time. Most of Advanced Proteome's value examination focuses on studying past and present price action to predict the probability of Advanced Proteome's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Advanced Proteome's price. Additionally, you may evaluate how the addition of Advanced Proteome to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |